Physician profile
Danielle Grontas
NPI 1497500805
$786.91
in general payments reported to CMS, 2019-2025
13 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $176 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $254.19 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $92.00 | 2024-2025 | Farxiga, Airsupra |
| Exact Sciences Corporation | $61.87 | 2024-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $61.80 | 2025 | Fanapt |
| Lundbeck LLC | $56.54 | 2025 | Rexulti |
| Amgen INC. | $51.76 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $51.29 | 2024-2025 | Capvaxive |
| Otsuka America Pharmaceutical, INC. | $39.79 | 2025 | Rexulti |
| Lilly USA, LLC | $38.16 | 2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $24.98 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.96 | 2025 | Jardiance |
| Eisai INC. | $16.70 | 2025 | |
| Glaxosmithkline, LLC. | $14.87 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Grontas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.